EntryPoint Capital’s ALX Oncology ALXO Stock Holding History

EntryPoint Capital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,847	Closed	-$31.7K	–	862
2024 Q1	$31.7K	Buy	+2,847	New	+$40K	0.03%	936

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

EntryPoint Capital's ALXO Position: Q2 2024 in Review

EntryPoint Capital sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 2,847 shares — an estimated $31.7K sold.

EntryPoint Capital first reported a position in ALXO in Q1 2024 and held it in 1 quarter. The position peaked at $31.7K in Q1 2024. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

EntryPoint Capital reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 2,847 ALX Oncology shares in Q2 2024, an estimated $31.7K.
EntryPoint Capital first reported a position in ALX Oncology in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's ALX Oncology position peaked at $31.7K in Q1 2024.
111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.